Cargando…
Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed
BACKGROUND: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. METHODS: Clinical characteristics and outcome of localized GN/GNBI were retrospec...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964292/ https://www.ncbi.nlm.nih.gov/pubmed/27465021 http://dx.doi.org/10.1186/s12885-016-2513-9 |
_version_ | 1782445077033910272 |
---|---|
author | Decarolis, Boris Simon, Thorsten Krug, Barbara Leuschner, Ivo Vokuhl, Christian Kaatsch, Peter von Schweinitz, Dietrich Klingebiel, Thomas Mueller, Ingo Schweigerer, Lothar Berthold, Frank Hero, Barbara |
author_facet | Decarolis, Boris Simon, Thorsten Krug, Barbara Leuschner, Ivo Vokuhl, Christian Kaatsch, Peter von Schweinitz, Dietrich Klingebiel, Thomas Mueller, Ingo Schweigerer, Lothar Berthold, Frank Hero, Barbara |
author_sort | Decarolis, Boris |
collection | PubMed |
description | BACKGROUND: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. METHODS: Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. RESULTS: Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months). Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection. Two patients died of treatment, none of tumor progression. CONCLUSIONS: GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifiers - NB97 (NCT00017225; registered June 6, 2001); NB2004 (NCT00410631; registered December 11, 2006) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2513-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4964292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49642922016-07-29 Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed Decarolis, Boris Simon, Thorsten Krug, Barbara Leuschner, Ivo Vokuhl, Christian Kaatsch, Peter von Schweinitz, Dietrich Klingebiel, Thomas Mueller, Ingo Schweigerer, Lothar Berthold, Frank Hero, Barbara BMC Cancer Research Article BACKGROUND: Ganglioneuroma (GN) and ganglioneuroblastoma intermixed (GNBI) are mature variants of neuroblastic tumors (NT). It is still discussed whether incomplete resection of GN/GNBI impairs the outcome of patients. METHODS: Clinical characteristics and outcome of localized GN/GNBI were retrospectively compared to localized neuroblastoma (NB) and ganglioneuroblastoma-nodular (GNBN) registered in the German neuroblastoma trials between 2000 and 2010. RESULTS: Of 808 consecutive localized NT, 162 (20 %) were classified as GN and 55 (7 %) as GNBI. GN/GNBI patients presented more often with stage 1 disease (68 % vs. 37 %, p < 0.001), less frequently with adrenal tumors (31 % vs. 43 %, p = 0.001) and positive mIBG-uptake (34 % vs. 90 %, p < 0.001), and had less often elevated urine catecholamine metabolites (homovanillic acid 39 % vs. 62 %, p < 0.001, vanillylmandelic acid 27 % vs. 64 %, p < 0.001). Median age at diagnosis increased with grade of differentiation (NB/GNBN: 9; GNBI: 61; GN-maturing: 71; GN-mature: 125 months, p < 0.001). Complete tumor resection was achieved at diagnosis in 70 % of 162 GN and 67 % of 55 GNBI, and after 4 to 32 months of observation in 4 GN (2 %) and 5 GNBI (9 %). Eleven patients received chemotherapy without substantial effect. Fifty-five residual tumors (42 GN, 13 GNBI) are currently under observation (median: 44 months). Five patients (3 GN, 2 GNBI) showed local progression; all had tumor residuals > 2 cm. No progression occurred after subtotal resection. Two patients died of treatment, none of tumor progression. CONCLUSIONS: GN/GNBI account for one quarter of localized NT and differ from immature tumors in their clinical features. Chemotherapy is not effective. Subtotal resection appears to be a sufficient treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifiers - NB97 (NCT00017225; registered June 6, 2001); NB2004 (NCT00410631; registered December 11, 2006) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2513-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-27 /pmc/articles/PMC4964292/ /pubmed/27465021 http://dx.doi.org/10.1186/s12885-016-2513-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Decarolis, Boris Simon, Thorsten Krug, Barbara Leuschner, Ivo Vokuhl, Christian Kaatsch, Peter von Schweinitz, Dietrich Klingebiel, Thomas Mueller, Ingo Schweigerer, Lothar Berthold, Frank Hero, Barbara Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed |
title | Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed |
title_full | Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed |
title_fullStr | Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed |
title_full_unstemmed | Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed |
title_short | Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed |
title_sort | treatment and outcome of ganglioneuroma and ganglioneuroblastoma intermixed |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964292/ https://www.ncbi.nlm.nih.gov/pubmed/27465021 http://dx.doi.org/10.1186/s12885-016-2513-9 |
work_keys_str_mv | AT decarolisboris treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT simonthorsten treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT krugbarbara treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT leuschnerivo treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT vokuhlchristian treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT kaatschpeter treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT vonschweinitzdietrich treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT klingebielthomas treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT muelleringo treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT schweigererlothar treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT bertholdfrank treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed AT herobarbara treatmentandoutcomeofganglioneuromaandganglioneuroblastomaintermixed |